Journals / Cardiovascular surgery and interventions / 2021 / Cilt: 8 - Sayı: 2

Patient and healthcare provider burden due to conventional measurement of theinternational normalized ratio: From a multi-dimensional perspective

Pages
70–77
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: A total of 1,259 laboratory entries were found for the overall study population.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:ABSTRACT Objectives: In this study, we aimed to investigate the healthcare burden associated with hospital visits for international normalized ratio(INR) measurement from a multi-dimensional perspective.
📊
Key Findings & Data:Patients and methods: A total of 415 patients (198 males, 217 females; mean age: 54±12.7 years; range, 14 to 84 years) who were admittedto the cardiovascular surgery (CVS) outpatient clinic between March 2015 and June 2015 were included.
💡
Conclusion & Impact:Results: A total of 1,259 laboratory entries were found for the overall study population.
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Abstract

ABSTRACT Objectives: In this study, we aimed to investigate the healthcare burden associated with hospital visits for international normalized ratio(INR) measurement from a multi-dimensional perspective. Patients and methods: A total of 415 patients (198 males, 217 females; mean age: 54±12.7 years; range, 14 to 84 years) who were admittedto the cardiovascular surgery (CVS) outpatient clinic between March 2015 and June 2015 were included. The burden of INR measurementwas assessed in two main categories: social and clinical. Data including educational status, occupational status and accompanying persons,indications for warfarin use, history of warfarin-related complications, expenses made by the patient and the accompanying persons, andthe time spent were recorded. Results: A total of 1,259 laboratory entries were found for the overall study population. Of these entries, 99.4% were only for INRmeasurements. An INR outside the target therapeutic range (TTR) was detected in 53.7% of the patients. Among all patients attending to theCVS outpatient clinic during the study, the sole reason for attendance was the INR measurement in 23%. The rate of complications requiringintervention was 2.1%. The daily clinical cost per patient was $22.14, the social monetary cost was $9.77, and the total cost was $31.91. Conclusion: Conventional INR measurements have a significant social and economic impact on patients and are associated withsignificantly increased workload and loss of resources from the perspective of the healthcare provider.

🔖

Cite This Article

KOCABEYOĞLU, S. S., KERVAN, Ü., KARAHAN, M., SERT, D. E., KAVASOĞLU, K., PAÇ, M., AYGÜN, E. (2022). Patient and healthcare provider burden due to conventional measurement of theinternational normalized ratio: From a multi-dimensional perspective. Cardiovascular surgery and interventions, Cilt: 8 - Sayı: 2, 70–77. https://ajindex.com/articles/471080

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):204S-233S
  2. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;123:2363-72
  3. Kaeberich A, Reindl I, Raaz U, Maegdefessel L, Vogt A, Linde T, et al. Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and highdose rivaroxaban in preventing thrombus formation on mechanical heart valves: Results of an in vitro study. J Thromb Thrombolysis 2011;32:417-25
  4. McKellar SH, Abel S, Camp CL, Suri RM, Ereth MH, Schaff HV. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. J Thorac Cardiovasc Surg 2011;141:1410-6
  5. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet 2014;383:955-62
  6. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206-14
  7. Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010;104:49-60
  8. Butchart EG, Payne N, Li HH, Buchan K, Mandana K, Grunkemeier GL. Better anticoagulation control improves survival after valve replacement. J Thorac Cardiovasc Surg 2002;123:715-23
  9. Rabin R, de Charro F. EQ-5D: A measure of health status from the EuroQol Group. Ann Med 2001;33:337-43
  10. Kahyaoğlu Süt H, Unsar S. Is EQ-5D a valid quality of life instrument in patients with acute coronary syndrome? Anadolu Kardiyol Derg 2011;11:156-62
  11. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:e57-185
  12. Baglin TP, Keeling DM, Watson HG; British Committee for Standards in Haematology. Guidelines on oral anticoagul